Principia Revealed In Generous IPO
SUCCESS STORIES
Principia Biopharma founded by Jack Taunton, began trading at $17.00 per share on the Nasdaq, raising approximately $122.2 million for immunology and cancer treatment.
FDA Clears FOR46 For Clinical Trials
SUCCESS STORIES
Fortis Therapeutics receives FDA clearance for two INDs to treat late-stage prostate cancer and multiple myeloma.
Radio Frequency Sedative Gets FDA Nod
SUCCESS STORIES
FDA grants 510(K) clearance to Relievant Medsystems leading to Its first commercial intracept procedures and $58 Million in equity funding.
Health Hub Launches in Collaboration with UCSF
Next-generation nonprofit Health Hub and UC San Francisco have announced plans to bring inventors and local entrepreneurs the support and professional development needed to build successful companies.
Venn Acquires Cancer Immunotherapy Antibody
Venn Therapeutics has completed an exclusive licensing deal with the University of California, San Francisco (UCSF) to advance its novel integrin αvβ8 antibody, created by a team of preeminent scientists at UCSF, led by Dr. Stephen Nishimura.
Cell Design Labs
SUCCESS STORIES
Producing cancer-fighting cell therapies, UCSF startup, Cell Design Labs Inc. was acquired by Gilead for $567M.
Okada's Lab Targets Novel 'Neoantigen'
SUCCESS STORIES
Hideho Okada's lab leads the way for new immunotherapy for deadly childhood brain cancer.

As part of our public mission, UC San Francisco strives to translate our scientific discoveries for public use and benefit. Whether it’s a new drug molecule, diagnostic, medical device or digital health application, our goal is to ensure the best new therapies and technologies can make their way to the patient as efficiently and safely as possible.

From Innovation...